What Causes Anxiety with Adenomyosis?

What Causes Anxiety with Adenomyosis?

Yes — anxiety is a genuine biological consequence of adenomyosis, not a psychological reaction to having a difficult diagnosis. Chronic inflammation, estrogen dominance, cortisol dysregulation, and mitochondrial stress all converge to destabilize the nervous system. The main caveat: anxiety severity tracks closely with disease burden, so symptom relief often requires addressing the underlying hormonal and inflammatory drivers, not anxiety in isolation.

Why Adenomyosis Disrupts the Nervous System

Adenomyosis is defined by endometrial tissue growing into the muscular wall of the uterus (myometrium). What makes it a whole-body condition is the inflammatory cascade it continuously produces. Pro-inflammatory cytokines — particularly IL-6, IL-1β, and TNF-α — are chronically elevated in adenomyosis tissue and circulate systemically (Benagiano et al., Human Reproduction Update 2012; PMID: 22343590). These cytokines cross the blood-brain barrier and directly activate microglial cells, the brain's resident immune cells, producing what researchers now call neuroinflammation.

Neuroinflammation, in turn, disrupts the tryptophan–kynurenine pathway. Instead of tryptophan being converted to serotonin, activated microglia shunt it toward the kynurenine pathway, producing quinolinic acid — an NMDA receptor agonist that is excitotoxic and strongly associated with anxiety and depression in clinical populations (Schwarcz et al., Nature Reviews Neuroscience 2012; PMID: 22678511). In practical terms: chronic peripheral inflammation actively reduces serotonin availability in the brain and simultaneously overstimulates glutamate receptors, a dual-hit mechanism that produces anxious arousal even in the absence of any external stressor.

This is why people with adenomyosis often describe anxiety that feels disproportionate — a racing heart, intrusive thoughts, or a persistent sense of dread that doesn't match their circumstances. It isn't catastrophizing; it is a measurable change in neurotransmitter flux driven by immune activation. Related symptoms that share this neuroinflammatory root include brain fog with adenomyosis and losing words mid-sentence, which frequently co-occur with anxiety in the same hormonal cycle window.

Estrogen Dominance and the GABA–Glutamate Imbalance

Adenomyosis is an estrogen-dependent condition. Ectopic endometrial cells express aromatase, locally producing estrogen and maintaining a self-sustaining hyperestrogenic environment independent of ovarian output (Bulun et al., Endocrine Reviews 2019; PMID: 30994175). Systemic estrogen excess — particularly when not opposed by adequate progesterone — has a well-documented effect on the anxious brain.

Estrogen at high, unbalanced levels upregulates corticotropin-releasing hormone (CRH) in the hypothalamus, sensitizing the HPA axis. This raises basal cortisol and makes the stress response fire more easily and recover more slowly. Progesterone, by contrast, is a potent positive allosteric modulator of GABA-A receptors through its neuroactive metabolite allopregnanolone. When progesterone is relatively low — as it is in estrogen-dominant states — GABA-A tone falls, reducing inhibitory neurotransmission and increasing excitability across limbic circuits. The result is a bias toward anxiety, irritability, and sleep fragmentation.

This hormonal anxiety tends to be cycle-dependent: it peaks in the luteal phase when the estrogen-to-progesterone ratio is most skewed, and it can worsen significantly in the days before menstruation. People with adenomyosis who also experience restless legs with adenomyosis or waking at 3am often report that these symptoms cluster in the same luteal window — consistent with a single underlying mechanism of low GABAergic tone and elevated cortisol.

Mitochondrial Dysfunction: The Energy Root of Anxious Arousal

Mitochondria are not peripheral to this story. The amygdala, the brain's threat-detection center, is among the most metabolically demanding brain regions, requiring a continuous and stable supply of ATP to regulate fear responses appropriately. When mitochondrial function is impaired — as it reliably is under conditions of chronic oxidative stress and systemic inflammation — the amygdala becomes hyperreactive, generating threat signals out of proportion to actual danger (Picard & McEwen, Biological Psychiatry 2018; PMID: 28985997).

Adenomyosis generates substantial oxidative stress. Reactive oxygen species (ROS) produced by ectopic lesion metabolism and macrophage infiltration deplete endogenous antioxidants including glutathione and CoQ10. A 2014 study measuring mitochondrial markers in endometriosis patients (a closely related condition sharing oxidative pathways) found significantly elevated 8-OHdG — a marker of oxidative DNA damage — compared to controls, suggesting systemic mitochondrial stress that extends well beyond the uterine lesion itself.

This is clinically meaningful: mitochondrial insufficiency in neural tissue doesn't just cause fatigue. It produces autonomic dysregulation — palpitations, shallow breathing, temperature dysregulation — that the brain interprets as somatic anxiety. This is why heart palpitations with adenomyosis and anxiety so often occur together; both reflect the same upstream problem of insufficient mitochondrial ATP production in autonomic regulatory circuits.

CoQ10 for Anxiety: Restoring Mitochondrial Calm

Coenzyme Q10 is a rate-limiting cofactor in the electron transport chain, shuttling electrons between complexes I–II and complex III. When CoQ10 is depleted by oxidative stress, mitochondrial membrane potential collapses and ROS production accelerates — a vicious cycle that worsens both peripheral inflammation and neural hyperexcitability.

In a randomized controlled trial of 80 patients with major depressive disorder, CoQ10 supplementation at 200 mg/day for 8 weeks produced a significant reduction in anxiety subscores compared to placebo, alongside measurable reductions in malondialdehyde (a lipid peroxidation marker) and increases in superoxide dismutase activity (Mehrpooya et al., Journal of Clinical Psychopharmacology 2018; PMID: 29438183). The anti-anxiety effect correlated with the degree of oxidative stress reduction — supporting a mechanism-based, not placebo, effect.

For someone with adenomyosis, CoQ10 at 200 mg as ubiquinol (the reduced, bioavailable form) addresses anxiety through at least two pathways: restoring neural ATP production and reducing the peripheral inflammatory burden that drives neuroinflammation. Ones formulas include CoQ10/Ubiquinol dosed at 200 mg — the same dose used in the Mehrpooya trial — calibrated into plans where a person's data shows elevated oxidative stress markers or mitochondrial load indicators.

Alpha-Lipoic Acid for Anxiety: The Blood-Brain Barrier Antioxidant

Alpha-lipoic acid (ALA) is uniquely positioned in this context because it is both fat- and water-soluble, allowing it to cross the blood-brain barrier and act directly within the central nervous system — a property most antioxidants lack. Once inside the brain, ALA regenerates glutathione, recycles vitamins C and E, and directly scavenges peroxynitrite, the reactive nitrogen species most damaging to neuronal mitochondria.

In a 12-week trial, ALA supplementation at 600 mg/day in patients with mild cognitive impairment reduced anxiety scores on the Hamilton Anxiety Rating Scale by 22% compared to baseline, an effect attributed to improved mitochondrial function and reduced oxidative modification of GABA-B receptors (which, when oxidized, become less responsive to their calming ligands). ALA also reduces TNF-α and IL-6 — two of the key cytokines elevated in adenomyosis — at doses of 600 mg/day in human trials (Namazi et al., Phytotherapy Research 2018; PMID: 29575206).

For a comprehensive overview of ALA's mechanisms and clinical dosing, see our article on alpha-lipoic acid for blood sugar and nerve health, which covers its anti-inflammatory and neuroprotective properties in detail.

PQQ for Anxiety: Mitochondrial Biogenesis and Neuroprotection

Pyrroloquinoline quinone (PQQ) is a redox cofactor that activates PGC-1α, the master regulator of mitochondrial biogenesis — essentially the signaling molecule that tells cells to build new, healthier mitochondria. This mechanism is distinct from CoQ10 (which optimizes existing mitochondrial function) and ALA (which reduces oxidative damage). PQQ works upstream, increasing the number and quality of mitochondria available to neural tissue.

A randomized crossover trial in 41 healthy adults found that 20 mg/day of PQQ for 8 weeks significantly improved scores on sleep quality, fatigue, and mood compared to placebo, with the largest effect sizes seen in participants who had elevated baseline fatigue — a profile consistent with the mitochondrial depletion seen in adenomyosis (Nakano et al., Functional Foods in Health and Disease 2012). PQQ also modulates the nerve growth factor (NGF) pathway, promoting neuronal survival and synaptic plasticity in limbic regions implicated in anxiety regulation.

While PQQ at 20 mg is a relatively small capsule footprint, its effects are synergistic with CoQ10 — the combination supports both biogenesis and function simultaneously, which is why they are often paired in mitochondrially-targeted formulas.

Pterostilbene for Anxiety: BDNF, Inflammation, and the Gut-Brain Axis

Pterostilbene is a methylated analog of resveratrol with significantly greater oral bioavailability (approximately 80% vs. less than 1% for resveratrol) and better CNS penetration. Its primary anxiolytic mechanisms center on three pathways: BDNF upregulation, NF-κB inhibition, and gut microbiome modulation.

Brain-derived neurotrophic factor (BDNF) is critical for neuroplasticity and resilience to stress. Low BDNF is consistently associated with anxiety disorders, and chronic inflammation — as seen in adenomyosis — suppresses BDNF expression. Pterostilbene at 50–100 mg/day has been shown in rodent models to increase hippocampal BDNF expression and reduce anxiety-like behavior on the elevated plus maze, effects that were blocked when BDNF was pharmacologically inhibited — confirming the causal pathway.

In human evidence, pterostilbene's NF-κB inhibition reduces IL-6 and TNF-α at doses of 50 mg twice daily, producing anti-inflammatory effects in cardiovascular and metabolic studies (Riche et al., Journal of Nutritional Biochemistry 2013; PMID: 22819549). Since it is the same cytokines driving adenomyosis-related neuroinflammation, the inference to anxiety reduction is mechanistically sound, even where direct adenomyosis trials are absent.

Pterostilbene also modulates the gut-brain axis by promoting Lactobacillus and Bifidobacterium species that produce GABA precursors and short-chain fatty acids — further supporting GABAergic tone that is suppressed in estrogen-dominant states.

Key Biomarkers to Track

If anxiety is a persistent symptom alongside adenomyosis, these are the most clinically actionable markers to assess:

Histamine overload can also worsen anxiety — excess histamine activates the sympathetic nervous system and disrupts sleep architecture. If anxiety spikes after eating fermented foods, aged cheese, or alcohol, histamine intolerance with adenomyosis may be a concurrent driver worth evaluating.

What This Means for Your Formula

Addressing anxiety with adenomyosis requires matching ingredients to the specific biological drivers showing up in your data — not a blanket anti-anxiety stack. Three ingredients are particularly well-supported for this symptom cluster:

CoQ10/Ubiquinol at 200 mg — Restores mitochondrial membrane potential in neural tissue, reduces oxidative-stress-driven neuroinflammation, and has direct trial evidence for anxiety score reduction at this dose (Mehrpooya et al., 2018; PMID: 29438183). This is the dose Ones includes when oxidative load or mitochondrial markers indicate depletion.

Alpha-Lipoic Acid at 600 mg — Crosses the blood-brain barrier to regenerate glutathione and reduce peroxynitrite damage to GABA receptors, while simultaneously lowering the circulating IL-6 and TNF-α that drive adenomyosis neuroinflammation. Ones uses ALA as an individual active within its ingredient catalog at clinical dosing.

Ones Adrenal Support blend — Targets the HPA axis dysregulation upstream of many anxiety symptoms. When cortisol patterns and symptom data indicate adrenal involvement, this proprietary blend is calibrated into the formula alongside targeted individual actives rather than as a default add-on.

Because Ones uses an AI-driven analysis of lab results, wearable data, and health history, the formula it builds reflects your specific pattern — whether that's mitochondrial depletion, estrogen dominance, histamine burden, or HPA hyperreactivity — rather than applying a generic anxiety protocol. The plan is selected by the AI based on what your data actually shows.

Key Takeaways

• Anxiety with adenomyosis has measurable biological causes: cytokine-driven neuroinflammation, estrogen-mediated GABA suppression, HPA axis sensitization, and mitochondrial insufficiency in neural tissue.
• The tryptophan–kynurenine pathway shunt reduces serotonin and elevates excitotoxic quinolinic acid, producing anxiety that is out of proportion to external circumstances.
• Cycle-dependent anxiety peaks in the luteal phase when the estrogen-to-progesterone ratio is most skewed and allopregnanolone-driven GABA-A tone is lowest.
• Mitochondrial support — particularly CoQ10 at 200 mg, ALA at 600 mg, and PQQ at 20 mg — addresses the energy deficit in amygdala regulation and reduces the peripheral oxidative stress feeding neuroinflammation.
• Pterostilbene supports BDNF expression and reduces NF-κB-driven cytokine production through a distinct mechanism, making it a useful complement to direct antioxidant support.
• Tracking hs-CRP, the estradiol-to-progesterone ratio, serum CoQ10, and cortisol diurnal pattern gives the clearest picture of which driver is dominant in any individual — and which intervention is most likely to help. Always consult a healthcare provider before changing your supplement protocol, particularly when hormonal conditions are involved.